BASF’s Personal Care division has launched a synthetic peptide designed for skincare applications, marking a significant step forward in the “slow-aging” trend. The new ingredient, Pepsensyal (INCI: mannitol, acetyl sh-tetrapeptide-1, and lauroyl sh-tetrapeptide-1), is clinically proven to reduce the first visible signs of aging by enhancing the skin’s natural regenerative process. The peptide works by smoothening, re-densifying, and resurfacing the skin, providing an innovative approach to maintaining youthful skin.
BASF explains that Pepsensyal aligns with the growing trend among consumers who prefer “slow-aging” over fighting the natural aging process. “Rather than fighting the natural aging process, consumers are increasingly concerned with healthy aging through a holistic, preventative approach to skin care,” BASF notes. This shift in consumer attitude is driving the demand for products that promote long-term skin health and rejuvenation, rather than focusing solely on erasing visible signs of aging.
Pepsensyal expands BASF’s peptide portfolio with a unique selling point: it is marketed as a cost-effective ingredient that is free from preservatives and derived from 99% natural sources. The company highlights that peptides have gained significant traction in the personal care market, with consumers recognizing their effectiveness as scientifically-backed, potent ingredients.
BASF Launches ‘Slow-Aging’ Pepsensyal Powered by Human Biopeptide is backed by extensive in vitro testing, which has confirmed its ability to support skin regeneration and slow the visible signs of aging. A double-blind, randomized, split-face clinical trial with 32 women aged 44 to 64 demonstrated the peptide’s effectiveness. After just 14 days of use, participants observed a noticeable improvement in the appearance of crow’s feet, with a reduction of 11% in roughness and 14% in maximum relief amplitude. Additionally, skin isotropy—indicating skin resurfacing—improved by 15%.
After 28 days of use, the clinical trial also showed that Pepsensyal contributed to the re-densification of the skin, with a 21% increase in the echogenic surface area of the dermis, indicating deep skin nourishment and rejuvenation. These results confirm the efficacy of Pepsensyal in replenishing the skin from within and delivering a visibly firmer, smoother appearance.
BASF Launches ‘Slow-Aging’ Pepsensyal Powered by Human Biopeptide as part of its ongoing commitment to providing cutting-edge skincare solutions. BASF continues to innovate in the skincare sector by expanding its peptide offerings and aligning with consumer preferences for natural, science-backed ingredients. In addition to this launch, the company has been presenting other advancements at international events, including AI-driven technologies at the 34th Congress of the International Federation of Societies of Cosmetic Chemists in Brazil.
In other recent developments, BASF introduced new natural-based biodegradable emulsifiers, such as the Emulgade Verde line, which suits cold manufacturing processes and can be used in sprayable emulsions, including sun care sprays. This aligns with the company’s broader strategy to replace synthetic ingredients with more sustainable alternatives.
BASF Launches ‘Slow-Aging’ Pepsensyal Powered by Human Biopeptide reflects BASF’s continued dedication to providing the beauty and personal care industry with products that not only support healthy aging but also meet the growing demand for eco-friendly, natural ingredients. With its emphasis on scientific research and sustainability, BASF remains a key player in the evolution of skincare technology.
